The company faces serious regulatory and financial challenges including non-compliance with NYSE American listing standards, stockholders' equity below minimum requirements ($1.8M vs. $2.0M required), five consecutive years of net losses, and risk of delisting if compliance is not achieved by October 2, 2027. These factors indicate significant financial distress and operational challenges.
Matinas BioPharma Holdings news
$2.53−92.97%
Close Sep 28, 2026 · split-adjustedToday's change is unusually large and no split is on record yet; it may reflect an unadjusted corporate action.
Articles · 30 days1English, de-duplicated
Positive00% of coverage
Neutral00%
Negative1100% of coverage
About Matinas BioPharma Holdings
GlobeNewswire Inc.Sep 4, 5:00 PM ET▼ Negative
Also mentions MTNB
Articles that tag MTNB but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology